Yellow fever kills more than 100 people in Darfur; WHO, health ministry to provide immunizations

Published on November 15, 2012 at 5:59 AM · No Comments

"More than two million people in Sudan's Darfur region will be vaccinated against a rare yellow fever outbreak suspected of killing 107 people since late September, health officials said on Tuesday," Agence France-Presse/France 24 reports (11/13). In a joint statement, the WHO and the Sudanese Ministry of Health said the mosquito-borne disease has spread throughout the western territory, which "has been plagued by conflict since rebels took up arms in 2003," Reuters notes (Dziadosz, 11/13). The International Coordinating Group on Yellow Fever Vaccine Provision, a WHO partnership with vaccine manufacturers, will provide the vaccines, according to VOA News (Lipin, 11/13). Anshu Banerjee of the WHO office in Sudan "said that while no yellow fever cases have been found outside Darfur, the WHO is planning a risk assessment in the next two weeks on the assumption that all areas in Sudan may be at risk of infection," the Associated Press reports. "The WHO estimates that more than 500 million people in 32 countries in Africa are at risk of yellow fever infection," the news service notes (Fick, 11/13).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Posted in: Disease/Infection News | Healthcare News

Tags: , , , ,

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Dry powdered measles vaccine triggers no adverse side effects in early human testing